Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Ji Kon Ryu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8798-0491; OpenAlex author ID A5045716213. Sources: ClinicalTrials.gov.

Their work

Papers
44 (first author 7, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
84
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 2 papers · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers, 1 trial · 2018: 3 papers · 2019: 4 papers · 2020: 2 papers · 2021: 5 papers · 2022: 5 papers · 2023: 2 papers · 2024: 6 papers · 2025: 1 paper · 2026: 4 papers

Papers 44

  1. Lorazepam and Survival in Asian Patients with Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.1007/s12029-026-01429-7↗
  2. Characteristics of Pancreatic Cancer-associated Ascites and Redefined Criteria for Bacterial Peritonitis. Last author DOI 10.1097/mpa.0000000000002606↗
  3. Treatment Outcomes in Frail Patients with Advanced Pancreatic Ductal Adenocarcinoma: A Real-World Comparison of Gemcitabine, S-1, and Stereotactic Ablative Rad… Co-author DOI 10.1159/000552276↗
  4. Ferroptosis-based therapeutic strategy targeting iron metabolism and SLC7A11 overcomes oxaliplatin resistance in patient-derived pancreatic cancer organoids. Co-author DOI 10.1186/s13046-026-03745-z↗
  5. ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167625↗
  6. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.12049↗
  7. Safety and Efficacy of Neoadjuvant SABR in Pancreatic Cancer: Effect of Magnetic Resonance Imaging-Guided Respiratory-Gated Adaptive Radiation Therapy. Co-author DOI 10.1016/j.adro.2023.101312↗
  8. Factors affecting peripheral neuropathy induced by nanoparticle albumin-bound paclitaxel in patients with pancreatic cancer. Co-author DOI 10.1111/bcp.16210↗
  9. Enhanced Anti-tumor Effect of Flavopiridol in Combination With Gemcitabine in Pancreatic Cancer. Last author DOI 10.21873/anticanres.16905↗
  10. Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib. Co-author DOI 10.3390/cancers16051056↗
  11. Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. Co-author DOI 10.4062/biomolther.2023.109↗
  12. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Co-author DOI 10.1002/jhbp.1050↗
  13. Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers15092642↗
  14. Cytokine-Induced Killer Cell Immunotherapy Combined With Gemcitabine Reduces Systemic Metastasis in Pancreatic Cancer: An Analysis Using Preclinical Adjuvant T… Co-author DOI 10.1097/mpa.0000000000002176↗
  15. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic a… Co-author DOI 10.1177/17588359221119539↗
  16. Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. Co-author DOI 10.3233/cbm-210490↗
  17. Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX. Co-author DOI 10.3389/fonc.2022.945829↗
  18. Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies. Co-author DOI 10.5009/gnl210166↗
  19. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, p… Co-author DOI 10.1177/17588359211056179↗
  20. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching … Co-author DOI 10.1186/s12885-021-08277-7↗
  21. Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Ca… Co-author DOI 10.3390/cancers13061196↗
  22. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. Co-author DOI 10.5009/gnl19182↗
  23. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
  24. Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2020.05.005↗
  25. Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach. First author DOI 10.5306/wjco.v11.i9.747↗
  26. The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort. Co-author DOI 10.1002/cam4.2617↗
  27. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Co-author DOI 10.1002/jhbp.648↗
  28. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment. Co-author DOI 10.1186/s12885-019-6193-0↗
  29. Comparison of Adjuvant Chemotherapy and Chemoradiation Therapy Efficacy for Pancreatic Cancer After R0 Resection: A Propensity Score-Matched Analysis First author DOI 10.21203/rs.2.12295/v1↗
  30. Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells. Co-author DOI 10.21873/anticanres.12624↗
  31. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. Co-author DOI 10.2214/ajr.17.18310↗
  32. Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. First author DOI 10.5009/gnl18220↗
  33. Preoperative Assessment of Pancreatic Cancer with FDG PET/MR Imaging versus FDG PET/CT Plus Contrast-enhanced Multidetector CT: A Prospective Preliminary Study. Co-author DOI 10.1148/radiol.2016152798↗
  34. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. First author DOI 10.5009/gnl16307↗
  35. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer. First author DOI 10.1111/jgh.13075↗
  36. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. Last author DOI 10.3346/jkms.2015.30.7.917↗
  37. [Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer]. Co-author DOI 10.4166/kjg.2015.66.3.150↗
  38. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who hav… Co-author DOI 10.1159/000356158↗
  39. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 p… Co-author DOI 10.1371/journal.pone.0078977↗
  40. The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer. First author DOI 10.1097/mpa.0b013e318221c903↗
  41. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318249d62e↗
  42. Postoperative prognostic predictors of pancreatic ductal adenocarcinoma: clinical analysis and immunoprofile on tissue microarrays. Co-author DOI 10.1245/s10434-012-2277-7↗
  43. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer. First author DOI 10.1097/mpa.0b013e3182156d5a↗
  44. Concurrent chemotherapy and pulsed high-intensity focused ultrasound therapy for the treatment of unresectable pancreatic cancer: initial experiences. Co-author DOI 10.3348/kjr.2011.12.2.176↗

Trials 1

  1. Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer Principal investigator NCT03214991↗

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sang Hyub Lee · 34 shared papers, 2011–2026 · strength 4.81
  2. Woo Hyun Paik · 28 shared papers, 2013–2026 · strength 4.53
  3. Yong‐Tae Kim · 28 shared papers, 2011–2025 · strength 3.29
  4. In Rae Cho · 13 shared papers, 2021–2026 · strength 2.85
  5. Jin Ho Choi · 15 shared papers, 2018–2026 · strength 2.62
  6. Jin‐Young Jang · 10 shared papers, 2017–2024 · strength 1.28
  7. Wooil Kwon · 8 shared papers, 2019–2024 · strength 1.14
  8. Eui Kyu Chie · 5 shared papers, 2021–2026 · strength 0.99
  9. Jung Won Chun · 6 shared papers, 2019–2025 · strength 0.85
  10. Ja‐Lok Ku · 4 shared papers, 2022–2026 · strength 0.76
  11. Hongbeom Kim · 5 shared papers, 2019–2024 · strength 0.72
  12. Do‐Youn Oh · 5 shared papers, 2018–2024 · strength 0.66
  13. Min Su You · 6 shared papers, 2018–2021 · strength 0.64
  14. Gunn Huh · 5 shared papers, 2018–2021 · strength 0.58
  15. Tae Seung Lee · 2 shared papers, 2024–2026 · strength 0.52
  16. J.H. Lee · 3 shared papers, 2022–2024 · strength 0.48
  17. Sang Kook Lee · 3 shared papers, 2022–2024 · strength 0.48
  18. Sun‐Whe Kim · 6 shared papers, 2012–2021 · strength 0.48
  19. Sang Myung Woo · 4 shared papers, 2011–2025 · strength 0.41
  20. Kwang Hyun Chung · 3 shared papers, 2016–2024 · strength 0.40
  21. Jae Seung Kang · 3 shared papers, 2019–2023 · strength 0.37
  22. Woo Jin Lee · 2 shared papers, 2022–2025 · strength 0.35
  23. Min Woo Lee · 2 shared papers, 2023–2024 · strength 0.34
  24. Tae Seung Lee · 1 shared paper, 2026 · strength 0.33
  25. Chang Hyun Kim · 1 shared paper, 2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.